Chidozie (Dozie) Amuzie
Dr. Chidozie (Dozie) Amuzie is a Scientific Director within the global pathology team at Janssen R&D. He received a PhD comparative medicine and integrative biology, combined with integrative toxicology at Michigan State University in 2009, and subsequently completed an anatomic pathology residency the same institution. He is board-certified in both toxicology and pathology, and enjoys combining the tools of toxicology and pathology to solve scientific problems. In his current role, Dozie provides scientific input in the design, conduct, and interpretation of experiments that focus on characterizing the safety of novel therapeutics and/or understanding mode(s) of action for toxicity in nonclinical studies. He also helps to ensure that pathology data from FIH-enabling studies for Janssen’s biologics portfolio are integrated and decision-quality. In addition, he is the therapeutic area pathologist for Janssen’s immunology portfolio, providing end to end nonclinical pathology support for the portfolio. Prior to joining Janssen R&D, Dozie was the Associate Director of Pathology at MPI Research (Mattawan, MI), where he spent about 5 years, in various pathology roles, working on diverse nonclinical safety assessment studies, and providing scientific leadership for the biomarker and investigative pathology unit. Dozie also assisted the Director of Pathology in pathology operations and pathologists. Dozie has authored/co-authored 5 books/book chapters, 15 peer-reviewed manuscripts and over 25 abstracts in toxicology and related disciples- immunotoxicology, biomarker identification and use, toxicokinetics, biopharmaceutical safety assessment, and animal models of cardiovascular and metabolic diseases. He has been invited to speak at several toxicology and pathology conferences globally. He is active in professional toxicology and toxicologic pathology organizations, and is currently the Vice President the Toxicology and Exploratory Pathology Specialty Section within the Society of Toxicology and Chair of the Immune System Interest Group within the Society of Toxicologic Pathology.